{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-25-000038","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.322026+00:00","generated_at":"2026-05-24T10:48:24.473135+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Senti Bio reports Q4 net loss $0.6M; two AML patients remain in remission from SENTI-202 trial","bullets":["Q4 net loss $0.6M ($0.67/share); full year net loss $52.8M ($12.03/share).","SENTI-202 Phase 1: 2 of 3 AML patients achieved MRD-negative CR; both still in remission as of March 2025.","Raised $47.6M gross from PIPE in Dec 2024; net $45.1M extends cash runway into 2026.","Cash $48.3M at Dec 31, 2024; received additional $1.5M from CIRM grant in Jan 2025.","Appointed Jay Cross CFO and Faraz Siddiqui SVP Tech Ops in Feb 2025; added two board members."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-25-000038","json":"https://secwatch.observer/filing/0001854270-25-000038.json","markdown":"https://secwatch.observer/filing/0001854270-25-000038.md","text":"https://secwatch.observer/filing/0001854270-25-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000038/0001854270-25-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000038/snti-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:48:24.473135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}